Overview

PK Study in Subjects With Severe Hepatic Impairment

Status:
Completed

Trial end date:
2019-03-25

Target enrollment:

Participant gender:

Summary

This is an open-label, single-dose study in male and female subjects with severe hepatic impairment and in male and female subjects with normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

Mitsubishi Tanabe Pharma Corporation

Treatments:

Antipyrine
Edaravone
Phenylmethylpyrazolone